Core Insights - The company reported a significant increase in product revenue for the first half of 2025, reaching 17.36 billion yuan, a year-on-year growth of 45.8% [1] - Total revenue for the same period was 17.52 billion yuan, reflecting a 46.0% increase compared to the previous year [1] - The net profit attributable to the parent company was 450 million yuan [1] Revenue Breakdown - The growth in product revenue was primarily driven by sales of self-developed products such as Baiyueze® (Zebutinib capsules) and licensed products from Amgen, as well as Baizean® (Tislelizumab injection) [2] - Baiyueze® achieved global sales of 12.53 billion yuan, marking a 56.2% year-on-year increase, with U.S. sales contributing 8.96 billion yuan, up 51.7% [2] - European sales of Baiyueze® totaled 1.92 billion yuan, a significant increase of 81.4%, while sales in China reached 1.19 billion yuan, growing by 36.5% [2] Product Performance - Baizean® recorded sales of 2.64 billion yuan, a 20.6% increase, driven by new indications approved for reimbursement in China [3] - Baiyueze® is noted for having the broadest range of approved indications among BTK inhibitors globally and is the only one with flexible dosing options [3] - The company has conducted over 35 clinical trials involving approximately 7,100 patients for Baiyueze®, which is now approved in 75 markets worldwide [3] R&D and Future Prospects - The company is advancing its next-generation self-developed pipeline products with a focus on rapid early clinical concept validation [4] - The global R&D team consists of over 3,700 personnel, collaborating with regulatory bodies and researchers across more than 45 countries [4] - The company anticipates over 20 milestone advancements in its hematological and solid tumor pipelines within the next 18 months [4]

Core Viewpoint - The announcement presents the preliminary financial data for BeiGene, Ltd. for the first quarter of 2025, highlighting significant revenue growth driven by the sales of its self-developed products, particularly Brukinsa and Tislelizumab, while also noting a net loss for the period [4][13]. Financial Data Summary - In Q1 2025, product revenue reached 7.985 billion RMB, a year-on-year increase of 49.9% [4] - Total operating revenue for Q1 2025 was 8.048 billion RMB, up 50.2% compared to the previous year [4] - The net profit attributable to the parent company was -0.095 billion RMB [4] - Total assets at the end of the reporting period were 42.126 billion RMB, a decrease of 1.7% from the beginning of the period [4] - Shareholder equity attributable to the parent company increased by 4.3% to 25.206 billion RMB [4] Product Performance - Global sales of Brukinsa totaled 5.692 billion RMB in Q1 2025, reflecting a 63.7% year-on-year growth [5] - In the U.S., sales of Brukinsa reached 4.041 billion RMB, a 61.9% increase, driven by demand growth, particularly in chronic lymphocytic leukemia (CLL) [5] - European sales of Brukinsa were 0.836 billion RMB, up 75.4%, attributed to market share gains in major European markets [5] - In China, Brukinsa sales amounted to 0.590 billion RMB, a 43.1% increase, maintaining a leading market position in the BTK inhibitor segment [5] Clinical Development and Regulatory Progress - Brukinsa is the most widely approved BTK inhibitor globally, with ongoing clinical trials in over 30 countries and regions [7] - The product has received approvals for multiple indications in the U.S., EU, and China, with plans for further regulatory submissions in 2025 [7] - Tislelizumab sales reached 1.245 billion RMB in Q1 2025, a 19.3% increase, driven by new indications and increased patient demand in China [6] - Tislelizumab has been approved for 14 indications in China, with a strong market presence in the PD-1 segment [6] Strategic Initiatives - The company is advancing its pipeline of next-generation products and emphasizes a rapid concept validation strategy in its global clinical development [9] - The internal R&D team consists of approximately 3,700 personnel, focusing on high-quality data generation and resource optimization [9] - The company plans to present data on various products, including antibody-drug conjugates and multi-specific antibodies, throughout 2025 [9] Corporate Developments - The company received shareholder approval to adopt a new English name, BeOne Medicines Ltd., and plans to relocate its registered office to Switzerland [12] - Recent patent decisions have favored the company, enhancing its intellectual property position [12] - An investor R&D day is scheduled for June 26, 2025, to showcase developments in breast cancer and broader solid tumor treatment portfolios [12]